NCT05319119

Brief Summary

This study is a retrospective, single-center study.This experiment aims to explore the influence of CT-FFR as a relevant for revascularization on the prognosis of patients with coronary heart disease, assessing concurrent on different basis the difference of prognosis of patients with revascularization was analyzed, and the significance of revascularization related by CT-FFR was analyzed.This study is a retrospective study. The treatment strategies of all patients are based on the results of CAG,including coronary revascularization.After calculating the CT-FFR value, the above doctors will formulate treatment strategies based on the results and formulate treatment strategies retrospectively.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 29, 2022

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

March 31, 2022

Completed
6 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 6, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 8, 2022

Completed
21 days until next milestone

Study Completion

Last participant's last visit for all outcomes

April 29, 2022

Completed
Last Updated

April 8, 2022

Status Verified

March 1, 2022

Enrollment Period

8 days

First QC Date

March 31, 2022

Last Update Submit

March 31, 2022

Conditions

Keywords

Fractional Flow ReserveCT-FFRprognosiscoronary Revascularization

Outcome Measures

Primary Outcomes (1)

  • All-cause death or Myocardial infarction

    Cardiovascular, non-cardiovascular and undetermined death or Target vessel related and non-target vessel related MI

    1 year

Secondary Outcomes (6)

  • Heart failure

    1 year,2 years

  • Non-target vessel revascularization

    1 year,2 years

  • Cardiac death

    1 year,2 years

  • Target vessel revascularization

    1 year,2 years

  • Myocardial infarction

    1 year,2 years

  • +1 more secondary outcomes

Study Arms (2)

1.CT-FFR Related Group

Coronary diseased artery CTFFR\>80%, secondary prevention of coronary heart disease;Coronary diseased artery CTFFR≤80% revascularization at the lesion site and regular medication after PCI

Coronary Angiography Related Group

Coronary diseased artery CTFFR≤80%, coronary angiography decision does not require revascularization but apply coronary heart disease secondary prevention medication;Coronary diseased artery CTFFR\>80%,However, revascularization was performed according to conventional angiographic decisions and postoperative regular service was performed.For multivessel disease, although coronary revascularization is performed, there are still diseased artery with CTFFR≤80% and no revascularization is performed.

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Diagnosed or suspected coronary heart disease patients with typical symptoms or objective evidence of ischemia such as ECG, exercise treadmill, coronary CTA or CAG

You may qualify if:

  • ①Diagnosed or suspected coronary heart disease patients during the diagnosis and treatment process
  • From December 2017 to December 2020, coronary CTA and coronary artery CTA were performed simultaneously in Huazhong Fuwai Hospital.
  • Patients with CAG (coronary CTA before coronary angiography after CAG, no more than 28 days apart).
  • ③Age 18 to 75 years old.

You may not qualify if:

  • ① The presence of severe artifact, dislocation or calcification in coronary CTA images affects FFRCT measurement. ② Contraindications to antiplatelet drugs
  • Patients with acute myocardial infarction within 6 months④ PCI or CABG or heart transplantation and other operations that may affect the outcome ⑤ Severe heart failure⑥ Pregnant patients⑦ Combined tumor patients⑧ Life expectancy \< 2 years⑨ Have a history of other serious heart disease⑩ Contraindications for CAG⑪ Not suitable to participate in this researcher due to other reasons

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fuwai Central China Cardiovascular Hospital

Zhengzhou, Henan, 450000, China

RECRUITING

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 31, 2022

First Posted

April 8, 2022

Study Start

March 29, 2022

Primary Completion

April 6, 2022

Study Completion

April 29, 2022

Last Updated

April 8, 2022

Record last verified: 2022-03

Locations